http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD
-
Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments
-
Sutro Biopharma Inc. (STRO) Reports Encouraging Interim Ph. 1 Clinical Data for Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
-
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
-
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
-
Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
-
Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
-
Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
-
Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
-
Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
-
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
-
Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
-
Sutro Biopharma Appoints James Panek to Board of Directors
-
Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference
-
Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference
-
Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments
-
Sutro Biopharma Inc. (STRO) Highlights Encouraging Prelim. Clinical Data in Ongoing Ph. I Study for STRO-002 Antibody-Drug Conjugate in Patients w/ Advanced Ovarian Cancer
-
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
-
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
-
Sutro Biopharma Inc. (STRO) to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
-
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
-
Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
-
Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments
-
Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference
-
Sutro Biopharma Inc. (STRO) Announces Connie Matsui as Board Chair
-
Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair
-
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
-
Sutro Biopharma Inc. (STRO) Reports Encouraging Interim Phase 1 Safety Data on STRO-001 for Treatment of B-cell Malignancies
-
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Ass
-
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
-
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
-
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
-
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
-
Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
-
Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
-
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
-
Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference
-
Sutro Biopharma Inc. (STRO) Secures $10M Milestone Payment from Celgene (CELG)
-
Sutro Achieves $10 Million Milestone Payment from Celgene
-
Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference
-
Sutro Biopharma Reports Third Quarter 2018 Financial Results
-
Sutro Biopharma Inc. (STRO) Reports IND Submission & Conclusion of 30-Day Review Period for STRO-002 in Phase 1 Clinical Study Evaluation
-
Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
-
Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
-
Sutro Biopharma, Inc. (STRO) Granted FDA Orphan Drug Designation for STRO-001 for Treatment of Multiple Myeloma
-
Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

